logo

Quick Facts

Share SHARE

The Hartford said that it has entered into an agreement with Prudential Financial Inc. (PRU) for the company's pension plan to purchase a group annuity contract and transfer $1.6 billion, or 29 percent of The Hartford's $5.6 billion in U.S. qualified pension plan liabilities. The agreement will transfer...

Martin Marietta Materials Inc. (MLM), a supplier of building materials, announced Monday that it has entered into a definitive agreement to buy Bluegrass Materials Co. for $1.625 billion in cash. Bluegrass, a unit of Panadero Aggregates Holdings, LLC, is the largest privately-held, pure-play aggregates...

Takeda Pharmaceutical Company Limited (TKPYY.PK) and Seattle Genetics Inc. (SGEN) announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival or PFS versus the control arm. ECHELON-1 is a randomized, multicenter...

Supervalu Inc. (SVU) said Monday that Bruce Besanko has informed the company's Board of Directors of his intention to resign his positions as Executive Vice President, Chief Operating Officer and Chief Financial Officer effective July 5, 2017 to pursue an opportunity outside the Company. The company...

Alnylam Pharmaceuticals, Inc. (ALNY), a RNAi therapeutics company, announced Monday new positive clinical results for Givosiran (ALN-AS1), an investigational RNAi Therapeutic for the treatment of acute Hepatic Porphyrias. The company said it plans to initiate Phase 3 Clinical Program in late 2017. The...

Rio Tinto Plc (RIO.L, RIO, RTNTF.PK) Monday confirmed Yancoal as the preferred buyer of its thermal coal assets in Australia. Rio Tinto said it prefers Yancoal for the high level of completion certainty and a further improved offer of $2.69 billion. Rio Tinto board has recommended its shareholders...

Takeda Pharmaceutical Company Limited (TKPYY.PK) Monday announced it has entered into a collaboration with privately held Biological E. Limited. Under the deal, Takeda will transfer its measles and acellular pertussis vaccine technologies to India-based Biological E. to develop low-cost combination vaccines...

As per a report published in The Wall Street Journal, Facebook Inc (FB) is in talks with major Hollywood studios and agencies regarding the production of scripted shows for the social network. Facebook declined to comment on the details of its plan. As per the report, Facebook has also proposed...

Nordex AG (NRDXF.PK) announced Erdem Holding A.S. has placed another order with the company to deliver and install a wind farm. The manufacturer is to supply ten N131/3900 turbines for the Eber wind farm. A Premium Service covering at least 15 years also forms part of the deal. The Eber project...

Fidelity National Information Services (FIS) announced it has commenced tender offers to purchase for cash up to $2 billion aggregate principal amount of its securities. The Tender Offers will expire on July 24, 2017. FIS also announced it intends to make an offering of senior notes denominated in...

Hikma Pharmaceuticals plc (HIK, HIK.L) announced the planned retirement of Michael Raya, CEO of the US business, effective at the end of the current year. The Group also announced organisational changes to the US business. From 1 July 2017, the US business will be organized into two entities:...

BHP (BHP.AX, BLT.L, BBL, BHP) announced approval of US$184 million in initial funding for the South Flank sustaining mine project in the central Pilbara, Western Australia. BHP President Operations, Minerals Australia, Mike Henry, said the funding would generate several hundred construction jobs and...

Genentech, a member of the Roche Group (RHHBY), reported positive data from the primary analysis of the Phase III HAVEN 1 study in adults and adolescents and interim analysis of the Phase III HAVEN 2 study in children evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) for the treatment...

Agios Pharmaceuticals, Inc. (AGIO) reported updated data from its pyruvate kinase-R (PKR) activator demonstrating the potential for the first disease-modifying treatment for patients with pyruvate kinase deficiency. DRIVE PK is an ongoing global open-label, Phase 2, safety and efficacy trial evaluating...

Verastem, Inc. (VSTM) reported long-term follow-up data from the DYNAMO study, which met its primary endpoint of Overall Response Rate at the final analysis. DYNAMO is a Phase 2 clinical study evaluating duvelisib, the company's investigational oral monotherapy, dual inhibitor of phosphoinositide-3-kinase...

Follow RTT